Prostaglandin E2 acts via bone marrow macrophages to block PTH-stimulated osteoblast differentiation in vitro

Bone

Volumn 56, Issue 1, 2013, Pages 31-41

  Choudhary, Shilpa ^a   Blackwell, Katherine ^a   Voznesensky, Olga ^a   Deb Roy, Abhijit ^a   Pilbeam, Carol ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Bone marrow stromal cells; Cyclooxygenase 2; EP2 receptor; EP4 receptor; Osteoclasts; Osteoprotegerin

Indexed keywords

COLONY STIMULATING FACTOR 1; CYCLOOXYGENASE 2; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E2; CULTURE MEDIUM; MESSENGER RNA; OSTEOCALCIN; PROSTAGLANDIN E RECEPTOR 2; PTGER2 PROTEIN, MOUSE; PTGER4 PROTEIN, MOUSE; PTGS2 PROTEIN, MOUSE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING SITE; BONE MARROW; CELL DIFFERENTIATION; CELL LINEAGE; CONTROLLED STUDY; IN VITRO STUDY; MACROPHAGE; MESENCHYMAL STEM CELL; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; ADIPOGENESIS; ANIMAL; BONE MARROW CELL; BOVINAE; CELL CULTURE; CULTURE MEDIUM; CYTOLOGY; DEFICIENCY; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HEMATOPOIETIC SYSTEM; KNOCKOUT MOUSE; METABOLISM; OSTEOBLAST; PHARMACOLOGY; STROMA CELL; BONE MARROW STROMAL CELLS; CATTLE; CYCLOOXYGENASE-2; DRUG EFFECT; EP2 RECEPTOR; EP4 RECEPTOR; OSTEOCLAST;

ADIPOGENESIS; ANIMALS; BONE MARROW CELLS; CATTLE; CELL DIFFERENTIATION; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; CYCLOOXYGENASE 2; DINOPROSTONE; GENE EXPRESSION REGULATION; HEMATOPOIETIC SYSTEM; MACROPHAGES; MICE; MICE, KNOCKOUT; OSTEOBLASTS; OSTEOCALCIN; PARATHYROID HORMONE; RANK LIGAND; RECEPTORS, PROSTAGLANDIN E, EP2 SUBTYPE; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE; RNA, MESSENGER; STROMAL CELLS;

BONE MARROW STROMAL CELLS; CYCLOOXYGENASE-2; EP2 RECEPTOR; EP4 RECEPTOR; OSTEOCLASTS; OSTEOPROTEGERIN;

EID: 84879292176     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.04.017     Document Type: Article

References (60)

1. Potts J.T., Gardella T.J. Progress, paradox, and potential: parathyroid hormone research over five decades. Ann N Y Acad Sci 2007, 1117:196-208.
2. Kim S.W., Pajevic P.D., Selig M., Barry K.J., Yang J.Y., Shin C.S., et al. Intermittent parathyroid hormone administration converts quiescent lining cells to active osteoblasts. J Bone Miner Res 2012, 27:2075-2084.
3. Lane N.E., Silverman S.L. Anabolic therapies. Curr Osteoporos Rep 2010, 8:23-27.
4. Iida-Klein A., Lu S.S., Kapadia R., Burkhart M., Moreno A., Dempster D.W., et al. Short-term continuous infusion of human parathyroid hormone 1-34 fragment is catabolic with decreased trabecular connectivity density accompanied by hypercalcemia in C57BL/J6 mice. J Endocrinol 2005, 186:549-557.
5. Horwitz M.J., Tedesco M.B., Sereika S.M., Prebehala L., Gundberg C.M., Hollis B.W., et al. A 7-day continuous infusion of PTH or PTHrP suppresses bone formation and uncouples bone turnover. J Bone Miner Res 2011, 26:2287-2297.
6. Robling A.G., Kedlaya R., Ellis S.N., Childress P.J., Bidwell J.P., Bellido T., et al. Anabolic and catabolic regimens of human parathyroid hormone 1-34 elicit bone- and envelope-specific attenuation of skeletal effects in Sost-deficient mice. Endocrinology 2011, 152:2963-2975.
7. Mendez-Ferrer S., Michurina T.V., Ferraro F., Mazloom A.R., Macarthur B.D., Lira S.A., et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 2010, 466:829-834.
8. Bellows C.G., Ishida H., Aubin J.E., Heersche J.N. Parathyroid hormone reversibly suppresses the differentiation of osteoprogenitor cells into functional osteoblasts. Endocrinology 1990, 127:3111-3116.
9. Swarthout J.T., D'Alonzo R.C., Selvamurugan N., Partridge N.C. Parathyroid hormone-dependent signaling pathways regulating genes in bone cells. Gene 2002, 282:1-17.
10. Wang Y.H., Liu Y., Buhl K., Rowe D.W. Comparison of the action of transient and continuous PTH on primary osteoblast cultures expressing differentiation stage-specific GFP. J Bone Miner Res 2005, 20:5-14.
11. Yang D., Singh R., Divieti P., Guo J., Bouxsein M.L., Bringhurst F.R. Contributions of parathyroid hormone (PTH)/PTH-related peptide receptor signaling pathways to the anabolic effect of PTH on bone. Bone 2007, 40:1453-1461.
12. 2 in cultured neonatal mouse calvariae. Endocrinology 1994, 135:1157-1164.
13. Tetradis S., Pilbeam C.C., Liu Y., Herschman H.R., Kream B.E. Parathyroid hormone increases prostaglandin G/H synthase-2 transcription by a cyclic adenosine 3',5'-monophosphate-mediated pathway in murine osteoblastic MC3T3-E1 cells. Endocrinology 1997, 138:3594-3600.
14. Pilbeam C.C., Choudhary S., Blackwell K.A., Raisz L.G. Prostaglandins and bone metabolism. Principles of bone biology 2008, 1235-1271. Elsevier/Academic Press, San Diego. J.P. Bilezikian, L.G. Raisz, T.J. Martin (Eds.).
15. Blackwell K.A., Raisz L.G., Pilbeam C.C. Prostaglandins in bone: bad cop, good cop?. Trends Endocrinol Metab 2010, 21:294-301.
16. Tian X.Y., Zhang Q., Zhao R., Setterberg R.B., Zeng Q.Q., Iturria S.J., et al. Continuous PGE2 leads to net bone loss while intermittent PGE2 leads to net bone gain in lumbar vertebral bodies of adult female rats. Bone 2008, 42:914-920.
17. Pilbeam C., Rao Y., Voznesensky O., Kawaguchi H., Alander C., Raisz L.G., et al. Transforming growth factor-b1 regulation of prostaglandin G/H syntase-2 expression in osteoblastic MC3T3-E1 cells. Endocrinology 1997, 138:4672-4682.
18. Chikazu D., Li X., Kawaguchi H., Sakuma Y., Voznesensky O.S., Adams D.J., et al. Bone morphogenetic protein 2 induces cyclo-oxygenase 2 in osteoblasts via a Cbfa1 binding site: role in effects of bone morphogenetic protein 2 in vitro and in vivo. 2002. J Bone Miner Res 2005, 20:1888-1898.
19. Choudhary S., Halbout P., Alander C., Raisz L., Pilbeam C. Strontium ranelate promotes osteoblastic differentiation and mineralization of murine bone marrow stromal cells: involvement of prostaglandins. J Bone Miner Res 2007, 22:1002-1010.
20. Xie C., Ming X., Wang Q., Schwarz E.M., Guldberg R.E., O'Keefe R.J., et al. COX-2 from the injury milieu is critical for the initiation of periosteal progenitor cell mediated bone healing. Bone 2008, 43:1075-1083.
21. Bonewald L.F., Johnson M.L. Osteocytes, mechanosensing and Wnt signaling. Bone 2008, 42:606-615.
22. Sugimoto Y., Narumiya S. Prostaglandin E receptors. J Biol Chem 2007, 282:11613-11617.
23. Li X., Liu H., Qin L., Tamasi J., Bergenstock M., Shapses S., et al. Determination of dual effects of parathyroid hormone on skeletal gene expression in vivo by microarray and network analysis. J Biol Chem 2007, 282:33086-33097.
24. Sakuma Y., Li Z., Pilbeam C., Alander C., Chikazu D., Kawaguchi H., et al. Stimulation of cAMP production and cyclooxygenase-2 by prostaglandin E2 and selective prostaglandin receptor agonists in murine osteoblastic cells. Bone 2004, 34:827-834.
25. Xu M., Choudhary S., Voznesensky O., Gao Q., Adams D., Diaz-Doran V., et al. Basal bone phenotype and increased anabolic responses to intermittent parathyroid hormone in healthy male COX-2 knockout mice. Bone 2010, 47:341-352.
26. Choudhary S., Huang H., Raisz L., Pilbeam C. Anabolic effects of PTH in cyclooxygenase-2 knockout osteoblasts in vitro. Biochem Biophys Res Commun 2008, 372:536-541.
27. Morham S.G., Langenbach R., Loftin C.D., Tiano H.F., Vouloumanos N., Jennette J.C., et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 1995, 83:473-482.
28. Kennedy C.R., Zhang Y., Brandon S., Guan Y., Coffee K., Funk C.D., et al. Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor. Nat Med 1999, 5:217-220.
29. Schneider A., Guan Y., Zhang Y., Magnuson M.A., Pettepher C., Loftin C.D., et al. Generation of a conditional allele of the mouse prostaglandin EP4 receptor. Genesis 2004, 40:7-14.
30. 2 receptor impairs osteoclastogenesis in vitro. Endocrinology 2000, 141:2054-2061.
31. Okada Y., Lorenzo J.A., Freeman A.M., Tomita M., Morham S.G., Raisz L.G., et al. Prostaglandin G/H synthase-2 is required for maximal formation of osteoclast-like cells in culture. J Clin Invest 2000, 105:823-832.
32. Zhan P., Alander C., Kaneko H., Pilbeam C.C., Guan Y., Zhang Y., et al. Effect of deletion of the prostaglandin EP4 receptor on stimulation of calcium release from cultured mouse calvariae: impaired responsiveness in heterozygotes. Prostaglandins Other Lipid Mediat 2005, 78:19-26.
33. Xu Z., Choudhary S., Okada Y., Voznesensky O., Alander C., Raisz L., et al. Cyclooxygenase-2 gene disruption promotes proliferation of murine calvarial osteoblasts in vitro. Bone 2007, 41:68-76.
34. Pilbeam C.C., Kawaguchi H., Hakeda Y., Voznesensky O., Alander C.B., Raisz L.G. Differential regulation of inducible and constitutive prostaglandin endoperoxide synthase in osteoblastic MC3T3-E1 cells. J Biol Chem 1993, 268:25643-25649.
35. Rickard D.J., Wang F.L., Rodriguez-Rojas A.M., Wu Z., Trice W.J., Hoffman S.J., et al. Intermittent treatment with parathyroid hormone (PTH) as well as a non-peptide small molecule agonist of the PTH1 receptor inhibits adipocyte differentiation in human bone marrow stromal cells. Bone 2006, 39:1361-1372.
36. Rosen C.J., Bouxsein M.L. Mechanisms of disease: is osteoporosis the obesity of bone?. Nat Clin Pract Rheumatol 2006, 2:35-43.
37. Muruganandan S., Roman A.A., Sinal C.J. Adipocyte differentiation of bone marrow-derived mesenchymal stem cells: cross talk with the osteoblastogenic program. Cell Mol Life Sci 2009, 66:236-253.
38. Shockley K.R., Lazarenko O.P., Czernik P.J., Rosen C.J., Churchill G.A., Lecka-Czernik B. PPARgamma2 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cells. J Cell Biochem 2009, 106:232-246.
39. Grundt A., Grafe I.A., Liegibel U., Sommer U., Nawroth P., Kasperk C. Direct effects of osteoprotegerin on human bone cell metabolism. Biochem Biophys Res Commun 2009, 389:550-555.
40. Han S.Y., Lee N.K., Kim K.H., Jang I.W., Yim M., Kim J.H., et al. Transcriptional induction of cyclooxygenase-2 in osteoclast precursors is involved in RANKL-induced osteoclastogenesis. Blood 2005, 106:1240-1245.
41. Pilbeam C.C., Raisz L.G., Voznesensky O., Alander C.B., Delman B.N., Kawaguchi K. Autoregulation of inducible prostaglandin G/H synthase in osteoblastic cells by prostaglandins. J Bone Miner Res 1994, 10:406-414.
42. Kobayashi Y., Take I., Yamashita T., Mizoguchi T., Ninomiya T., Hattori T., et al. Prostaglandin E2 receptors EP2 and EP4 are down-regulated during differentiation of mouse osteoclasts from their precursors. J Biol Chem 2005, 280:24035-24042.
43. Choudhary S., Alander C., Zhan P., Gao Q., Pilbeam C., Raisz L. Effect of deletion of the prostaglandin EP2 receptor on the anabolic response to prostaglandin E2 and a selective EP2 receptor agonist. Prostaglandins Other Lipid Mediat 2008, 86:35-40.
44. Gao Q., Zhan P., Alander C.B., Kream B.E., Hao C., Breyer M.D., et al. Effects of global or targeted deletion of the EP4 receptor on the response of osteoblasts to prostaglandin in vitro and on bone histomorphometry in aged mice. Bone 2009, 45:98-103.
45. Ishizuya T., Yokose S., Hori M., Noda T., Suda T., Yoshiki S., et al. Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells. J Clin Invest 1997, 99:2961-2970.
46. Karsdal M.A., Martin T.J., Bollerslev J., Christiansen C., Henriksen K. Are nonresorbing osteoclasts sources of bone anabolic activity?. J Bone Miner Res 2007, 22:487-494.
47. Pederson L., Ruan M., Westendorf J.J., Khosla S., Oursler M.J. Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc Natl Acad Sci U S A 2008, 105:20764-20769.
48. Kreja L., Brenner R.E., Tautzenberger A., Liedert A., Friemert B., Ehrnthaller C., et al. Non-resorbing osteoclasts induce migration and osteogenic differentiation of mesenchymal stem cells. J Cell Biochem 2010, 109:347-355.
49. Guihard P., Danger Y., Brounais B., David E., Brion R., Delecrin J., et al. Induction of osteogenesis in mesenchymal stem cells by activated monocytes/macrophages depends on oncostatin M signaling. Stem Cells 2012, 30:762-772.
50. Henriksen K., Andreassen K.V., Thudium C.S., Gudmann K.N., Moscatelli I., Cruger-Hansen C.E., et al. A specific subtype of osteoclasts secretes factors inducing nodule formation by osteoblasts. Bone 2012, 51:353-361.
51. Nicolaidou V., Wong M.M., Redpath A.N., Ersek A., Baban D.F., Williams L.M., et al. Monocytes induce STAT3 activation in human mesenchymal stem cells to promote osteoblast formation. PLoS One 2012, 7:e39871.
52. Chang M.K., Raggatt L.J., Alexander K.A., Kuliwaba J.S., Fazzalari N.L., Schroder K., et al. Osteal tissue macrophages are intercalated throughout human and mouse bone lining tissues and regulate osteoblast function in vitro and in vivo. J Immunol 2008, 181:1232-1244.
53. Winkler I.G., Sims N.A., Pettit A.R., Barbier V., Nowlan B., Helwani F., et al. Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs. Blood 2010, 116:4815-4828.
54. Alexander K.A., Chang M.K., Maylin E.R., Kohler T., Muller R., Wu A.C., et al. Osteal macrophages promote in vivo intramembranous bone healing in a mouse tibial injury model. J Bone Miner Res 2011, 26:1517-1532.
55. Walker E.C., McGregor N.E., Poulton I.J., Pompolo S., Allan E.H., Quinn J.M., et al. Cardiotrophin-1 is an osteoclast-derived stimulus of bone formation required for normal bone remodeling. J Bone Miner Res 2008, 23:2025-2032.
56. Negishi-Koga T., Shinohara M., Komatsu N., Bito H., Kodama T., Friedel R.H., et al. Suppression of bone formation by osteoclastic expression of semaphorin 4D. Nat Med 2011, 17:1473-1480.
57. Gao Q., Xu M., Alander C.B., Choudhary S., Pilbeam C.C., Raisz L.G. Effects of prostaglandin E2 on bone in mice in vivo. Prostaglandins Other Lipid Mediat 2009, 89:20-25.
58. Uppal S., Diggle C.P., Carr I.M., Fishwick C.W., Ahmed M., Ibrahim G.H., et al. Mutations in 15-hydroxyprostaglandin dehydrogenase cause primary hypertrophic osteoarthropathy. Nat Genet 2008, 40:789-793.
59. Kang Y.J., Mbonye U.R., Delong C.J., Wada M., Smith W.L. Regulation of intracellular cyclooxygenase levels by gene transcription and protein degradation. Prog Lipid Res 2007, 46:108-125.
60. Mbonye U.R., Wada M., Rieke C.J., Tang H.Y., DeWitt D.L., Smith W.L. The 19-amino acid cassette of cyclooxygenase-2 mediates entry of the protein into the endoplasmic reticulum-associated degradation system. J Biol Chem 2006, 281:35770-35778.